A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Public ClinicalTrials.gov record NCT04944992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Study identification
- NCT ID
- NCT04944992
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 145 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2021
- Primary completion
- Oct 18, 2022
- Completion
- Oct 18, 2022
- Last update posted
- Nov 14, 2023
2021 – 2022
United States locations
- U.S. sites
- 9
- U.S. states
- 4
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Catalina Research Institute, LLC ( Site 1939) | Montclair | California | 91763 | — |
| Sweet Hope Research Specialty, Inc ( Site 1902) | Hialeah | Florida | 33016 | — |
| Floridian Clinical Research, LLC ( Site 1950) | Miami Lakes | Florida | 33016 | — |
| Sensible Healthcare, LLC ( Site 1903) | Ocoee | Florida | 34761 | — |
| Lucas Research, Inc ( Site 1930) | Morehead City | North Carolina | 28557 | — |
| Texas Clinical Research Institute ( Site 1910) | Arlington | Texas | 76012 | — |
| Baylor College of Medicine-Advanced Liver Therapies ( Site 1960) | Houston | Texas | 77030 | — |
| American Research Corporation at Texas Liver Institute ( Site 1920) | San Antonio | Texas | 78215 | — |
| Clinical Trials of Texas, Inc. ( Site 1906) | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04944992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04944992 live on ClinicalTrials.gov.